Tildrakizumab is named as a drug or biological intervention in 2 clinical trials in our USA and India trial registers, none of which are currently recruiting. The lead sponsor is Sun Pharmaceutical Industries Limited. Registered phases: Phase 2/3 and Phase 3. Conditions studied include Moderate-to-severe Chronic Plaque Psoriasis; Moderate to Severe Genital Psoriasis.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06611163 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. (ClinicalTrials.gov ↗) Moderate to Severe Genital Psoriasis |
Phase 3 | Active, closed |
| NCT03997786 | A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis (ClinicalTrials.gov ↗) Moderate-to-severe Chronic Plaque Psoriasis |
Phase 2/3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Moderate-to-severe Chronic Plaque Psoriasis | 1 |
| Moderate to Severe Genital Psoriasis | 1 |
| Lead sponsor | Trials |
|---|---|
| Sun Pharmaceutical Industries Limited | 2 |
| Register | Tildrakizumab trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in India | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tildrakizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tildrakizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.